Evidence backs safety of sucralose but some don’t buy it

May 17 (UPI) — A recent decision by the European Food Safety Agency, or EFSA, on the safety of the artificial sweetener used in Splenda, sucralose, has some groups crying foul.

On May 8, the EFSA announced it believes sucralose to be safe and not carcinogenic, which is a conclusion shared by several regulatory agencies in the United States and Europe.

The EFSA said they do not believe the available data support conclusions by the controversial Ramazzini Institute that sucralose causes leukemia and related blood cancers in male mice.

The Ramazzini Institute is a research laboratory in Italy that has come under scrutiny over its testing methods and findings, including a 2016 finding that sucralose is a carcinogen.

The U.S. Food and Drug Administration, or FDA, approved sucralose for use in 15 food categories in 1998 and for use as a general purpose sweetener for foods in 1999, under certain conditions of use.

Sucralose has been extensively studied, with more than 110 safety studies reviewed by FDA for its approval as a general purpose sweetener for food.

“The testing required by regulatory agencies in the U.S. and around the world are incredibly detailed, comprehensive, and incorporate large margins of safety by using doses of the ingredients that far exceed those expected in humans,” Berna Magnuson, scientific and regulatory consultant for Heartland Sweeteners, the company that makes Splenda, told UPI.

“All agencies that have reviewed the database of safety studies for sucralose agree that the amounts used in foods and beverages are safe and have approved its use in their jurisdiction. Within each agency is a large team of independent experts that have carefully reviewed the totality of the safety data, and who continue to monitor studies that are published subsequent to approval, such as the study by the RI [Ramazzini Institute]. Not one has changed its approval. So consumers should have confidence that there has been extensive testing prior to…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *